Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Adding fluorine to drug molecules can be tricky, but is often worthwhile. Rachel Brazil talks to the chemists trying to tame ...

We torture-test a dozen of the most popular text-to-image AI tools with a series of prompts designed to highlight their strengths and weaknesses. Here's how they stack up. I've been writing about ...

Image Credit: ZinetroN / Shutterstock A team of investigators ... improving its ability to predict gene regulation across different cell types. The model, called EpiBERT, was inspired by BERT, a deep ...

Bearish flow noted in GSK (GSK) Pharma with 1,694 puts trading, or 4x expected. Most active are 2/7 weekly 34 puts and Jan-27 28 puts, with total volume in those strikes near 1,600 contracts.

Malaysia Image caption, Jannatul Maoua of Bangladesh catches out Asabi Callender of West Indies during their ICC Women's U19 T20 World Cup 2025 Super Six match at Bayuemas Oval in Kuala Lumpur ...

Viralgen and Axovia are developing an AAV9-based gene therapy for retinal dystrophy in Bardet-Biedl Syndrome (BBS) patients. The therapy aims to stop photoreceptor cell death and vision loss using a ...

Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or vaccines which target ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed last ...

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines. The University of Oxford and GSK are to work on a vaccine to target cells in the ...

(AP Photo/Martin Meissner) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Jan. 17-23, 2025 This photo gallery, curated by photo editor Bridget Jones, highlights some of the most ...